TREATMENT FOR OVARIAN CANCER
One of the most exciting things emerging in the biomedical fields currently is the idea of personalized medicine. Given a patient’s genetic makeup and risk factors, can we optimize treatment regimens to maximize impact on a patient’s prognosis and survival? Some key questions in this area include:
What is the biological basis for treatment resistance?
What combinations of mutations are more/less likely to respond to treatment?
How do various cell models respond to common chemotherapies?
Does genetic predisposition (e.g. BRCA mutations) play a role in treatment outcomes?